Kenneth Smith
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Kenneth Smith
Analyst Ratings for AMAG Pharmaceuticals and Peers in February
Of the 12 analysts covering AMAG Pharmaceuticals, three have given the stock a “buy” or higher rating, and nine have given it a “hold.”
How Bristol-Myers Squibb’s Key Products Performed in 1Q18
Total sales for Bristol-Myers Squibb’s Opdivo increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18.
Exploring Acorda Therapeutics’ Financial Performance
In fiscal 2017, Acorda Therapeutics (ACOR) generated total revenue of $588.2 million, compared with $519.6 million in fiscal 2016.
A Look at Sarepta Therapeutics’ Stock Performance
After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.
Analyst Recommendations for Ignyta and Its Peers in January 2018
Of the four analysts covering Ignyta in January 2018, all of them have given the stock a “hold” rating. The mean rating for the stock is 3.0 with a target price of $28.
How Spark Therapeutics Is Positioned in 2018
Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.
Analysts Rate Voyager Therapeutics and Its Peers in April
Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.
Understanding Tesaro’s Operational Performance
Tesaro’s (TSRO) selling, general, and administrative expenses increased from $92.98 million in Q2 2017 to $100.03 million in Q2 2018.
Taking Stock of Biogen’s Recent Performance
In the third quarter, Biogen’s net product revenue rose year-over-year to $2.78 billion from $2.62 billion.
What Analysts Recommend for Accelerate Diagnostics and Peers
Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.
Taking Stock of Regeneron Pharmaceuticals’ Marketed Products
Globally, Regeneron Pharmaceuticals’ (REGN) Eyelea generated $5.9 billion in sales in fiscal 2017 compared with $5.1 billion in fiscal 2016.
Analyzing AbbVie’s Financial Performance
AbbVie (ABBV) generated net revenue of $7.9 billion in 1Q18 compared to $6.5 billion in 1Q17.
Understanding Stryker’s Operational Performance
Stryker (SYK) incurred SG&A (selling, general, and administrative) expenses of $1.19 billion in the second quarter.
What Does Gilead Sciences’ Bottom-Line Trend Indicate?
Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter.
Exploring Stryker’s Business Segments
Products under the Orthopedics segment include implants used for hip and knee joint replacements and extremities surgeries.
How Intuitive Surgical Stock Has Performed in the Last Month
From a low of $376.92 on January 4, Intuitive Surgical (ISRG) stock rose to a high of $581.12 on October 1.
A Look at Nektar Therapeutics’ Financial Performance
Diversified revenue streams Nektar Therapeutics’ (NKTR) total revenue includes product sales, royalty revenue, non-cash revenue related to the sale of future royalties, and license and collaboration revenue. Nektar had product sales of $4.4 million in 3Q17, compared with $144.7 million in 3Q16. Between 3Q16 and 3Q17, its royalty revenue rose from $5.5 million to $9.3 million, and its license […]
A Look at Verastem’s Operational Performance
Verastem (VSTM) incurred general and administrative expenses of $15.8 million in Q2 2018 compared to $4.4 million in Q2 2017.
Gauging Analysts’ Views on Tesaro Stock
In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.
Analyzing the Cash Flows and Valuation Metrics of Akorn
Akorn (AKRX) used up $31.6 million in operating activities in 1Q18. In comparison, the company generated operating cash flow of $126.6 million in 1Q17.
Dentsply Sirona’s Segments: Q2 2018 Performance
Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%.
Key Risks Facing Marinus Pharmaceuticals in December 2017
Since inception in 2003, Marinus Pharmaceuticals (MRNS) has focused on the development of ganaxalone.
A Look at Insys Therapeutics’ Financial Performance
Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales.
Investors Still Excited about Axovant
Axovant is focusing on gene therapy candidates AXO-Lenti-PD and AXO-AAV-OPMD.
Analyzing the Performance of Celgene’s Hematology Portfolio
Celgene’s total worldwide sales of the hematology/oncology category increased from $2.7 billion in 1Q17 to $3.1 billion in 1Q18.
How AbbVie Fared in Q2 2018
Driven by growth in Humira, Imbruvica, and Mavyret sales, AbbVie (ABBV) delivered strong Q2 2018 results on July 27.
Do Analysts See Any Upside in BeiGene Stock?
Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”
What Spark Therapeutics’ Valuation Trend Indicates
Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
Performance of Celgene’s Inflammation and Immunology Products
Total worldwide sales of Celgene’s other products—including Idhifa, Thalomid, and Istodax—increased from $226.0 million in 1Q17 to $229.0 million in 1Q18.
Analyzing Geron’s Financial Performance
In Q1 2018, Geron’s (GERN) license fee and royalty revenue fell YoY (year-over-year) to $318,000 from $537,000, with license fee revenue falling YoY to $248,000 from $409,000.
Key Risks Facing Sucampo Pharmaceuticals in 2017
Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.
Sucampo Pharmaceuticals’ Research Pipeline in December 2017
Sucampo Pharmaceuticals (SCMP) recently completed a Phase 3 study for the alternate sprinkle formulation of Amitiza (lubiprostone) in adults with CIC (chronic idiopathic constipation).
Exploring Novavax’s Vaccine Candidates for RSV
According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.
An Overview of Spectrum Pharmaceuticals’ Drug Pipeline
Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.
Spectrum Pharmaceuticals’ Product Licensing Agreements
In 2012, Spectrum Pharmaceuticals (SPPI) acquired the rights to market Zevalin outside the US from Bayer for 19 million euros.
Riot Blockchain’s Recent Investments in the Cryptocurrency Space
In October 2017, Riot Blockchain (RIOT) acquired a 52% stake in Tess, a developer of blockchain solutions for telecom (telecommunications) companies.
Analyzing Baxter International’s Operational Performance
Baxter International’s net interest expense decreased from $13 million in the second quarter of 2017 to $11 million in the second quarter of 2018.
What Stryker’s Bottom-Line Trend Indicates
Stryker’s (SYK) net other expense decreased from $54.0 million in the third quarter of 2017 to $42.0 million in the latest quarter.
Analyzing the Performance of Danaher’s Dental Business
Danaher Corp.’s (DHR) enterprise value is $85.21 billion, and its enterprise-value-to-revenue ratio is 4.42.
How’s Athenex’s Financial Performance?
In fiscal 2017, Athenex (ATNX) generated total revenues of $38 million—compared to $20.5 million in fiscal 2016.
Chart in Focus: Novavax’s Financial Position in 2017
Novavax (NVAX) generated revenues of $8.4 million in 3Q17 compared with $3.2 million in 3Q16.
Exploring ViewRay’s Operational Performance
ViewRay incurred general and administrative expenses of $10.5 million in the second quarter compared to $7.46 million in the second quarter of 2017.
These Pharma Stocks Offer the Most Upside Potential
In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.
Tandem Diabetes Care Continues Its Strong Performance in Q2 2018
Tandem Diabetes Care’s (TNDM) t:slim X2 with Basal-IQ, which is its automated insulin delivery algorithm, was approved by the FDA in June.
How Was Nektar Therapeutics’ Top-Line Performance?
In the first quarter, Nektar Therapeutics (NKTR) generated total revenues of $38 million compared with $24.7 million in the first quarter.
The Financial Performance of Integer Holdings Corporation
The total revenues of Integer Medical Holdings (ITGR) grew from $1.3 billion in fiscal 2016 to $1.4 billion in fiscal 2017.
Examining Abiomed’s Gross Margin Trend
In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.
Athenex’s Product Groups and Geographic Performance
The majority of Athenex’s revenues in Q1 2018 came from API sales, commercial product sales, and license fees.
Exploring Waters Corporation’s Operational Performance
Waters Corporation (WAT) incurred selling and administrative expenses of $136.6 million in the second quarter.
Major Expected Events from AstraZeneca’s R&D in H2 2018
AstraZeneca has seen major recent product approvals such as Lynparza in Japan for breast cancer and Tagrisso in the EU for lung cancer.
Analyzing Athenex’s Cash Flows
In fiscal 2017, Athenex (ATNX) incurred interest expenses of $5.9 million—compared to $1.8 million in fiscal 2016.
Exploring Geron’s Financial Performance
In fiscal 2017, Geron (GERN) generated revenues of $1 million through license fees and royalties compared with $6.1 million in fiscal 2016.
Baxter International’s Global Business Units in Q1 2018
Sales for Renal Care increased 10% from $789 million in Q1 2017 to $868 million in Q1 2018.
Exploring Almost Family’s Financial Performance
In 2017, Almost Family (AFAM) generated net service revenue of $796.9 million compared to $623.5 million in 2016.
Ignyta’s Drug Pipeline
Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.
A Close Look at Ignyta’s Licensing Agreement
Ignyta (RXDX) entered into a licensing agreement with Nerviano Medical Sciences in which Ignyta has exclusive global rights to develop and commercialize entrectinib.
Inside Ignyta’s Financial Performance
Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.
Ignyta and Its Key Risks in 2018
In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.
Analyzing Seattle Genetics’ Key Collaborations
Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.
How Boston Scientific Is Expected to Perform in the Third Quarter
Boston Scientific (BSX) is expected to report its third-quarter earnings on October 24.
Why Alnylam’s Clinical Pipeline Seems Promising
Alnylam Pharmaceuticals’ (ALNY) target indications include genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases.
Do Analysts See Any Upside for Thermo Fisher Stock?
Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”
Thermo Fisher Scientific’s Gross Margin Trends
In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
Taking Stock of Thermo Fisher as the Year Wraps Up
In this series, we’ll explore Thermo Fisher’s financials and valuation, and analysts’ views on its stock.
Taking Stock of BeiGene’s Latest Performance
BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Do Analysts See Any Upside for Abiomed Stock?
In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.
Exploring Abiomed’s Latest Performance Trends
In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.
Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.
Do Analysts See Any Upside for Vertex Stock?
Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”
Vertex Pharmaceuticals’ Gross Margin Trends
Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.
Taking Stock of Vertex’s Performance
Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.
Do Analysts See Any Upside for bluebird bio Stock?
In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.
Understanding bluebird bio’s Operational Performance
In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
Sage Therapeutics’ Operational Performance
In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.
Sage Therapeutics: Analyzing New Product Candidates
The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.
Do Analysts See Any Upside for Ionis Stock?
Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds.”
Taking Stock of Ionis’s Performance
Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.
Taking Stock of DaVita’s Performance
In the third quarter, DaVita’s total revenue rose YoY (year-over-year) to $2.85 billion from $2.76 billion.
Do Analysts See Any Upside for Biogen Stock?
Of the 29 analysts covering Biogen (BIIB), 20 have given it “buy” or higher ratings, and nine have given it “hold” ratings.
Abbott Laboratories’ Gross Margin Trends
In fiscal 2018 and fiscal 2019, Abbott Laboratories (ABT) is expected to generate revenue of $30.66 billion and $32.21 billion, respectively, compared with revenue of $27.39 billion in fiscal 2017.
Health Check: How Abbott Laboratories is Positioned
Abbott Laboratories (ABT) offers products in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Cardiovascular and Neuromodulation Products.
Do Analysts See Any Upside for Regeneron Stock?
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”
What Seattle Genetics’ Bottom-Line Trend Indicates
In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.
How’s Seattle Genetics Positioned?
Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
Regeneron Pharmaceuticals’ Gross Margin Trends
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.
How Much Upside Do Analysts Expect in Endo Stock?
In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating.
How Tandem Diabetes Care Stock Has Fared in the Last Month
After a phenomenal run from $2.52 on January 5 to a high of $51.17 on September 13, Tandem Diabetes Care (TNDM) stock slid.
How Illumina Stock Has Fared in the Last Month
After witnessing a rise from $209.54 on February 8 to a high of $372.61 on September 28, Illumina (ILMN) stock corrected to $289.50 on October 24.
How XRAY’s Performance Has Shaken Out over the Last Month
Dentsply Sirona stock witnessed a steady uptick in November, rising from $34.58 on November 6 to $37.78 on November 30.
How Hologic Stock Has Fared in the Last Month
After rising from $36.53 on April 9, 2018, to $42.91 on July 31, 2018, Hologic (HOLX) stock slid to $37.90 on October 29, 2018.
How Has Edwards Lifesciences Stock Fared in the Last Month?
After witnessing strong gains from $115.41 on January 4, 2018, to a high of $174.10 on September 28, 2018.
How These Medical Equipment Stocks Have Fared in the Last Month
In December 2018, of the total 15 analysts covering Align Technology, 13 analysts have given the stock a “buy” or higher rating.
Taking Stock of Sangamo’s Financial Performance
In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.
An Overview of Array BioPharma Stock
Array BioPharma generated total revenue of $56.91 million in the first quarter of fiscal 2019.
Analysts Remain Bullish on Illumina Stock
In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.
Understanding Illumina’s Gross Margin Trend
Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.
Understanding Illumina’s Geographical Performance
For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.
Taking Stock of Edwards Lifesciences’ Performance
A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.
What Does Dentsply’s Bottom-Line Trend Indicate?
Dentsply Sirona’s interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter.
